2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-122237
    ATZ-1993 219705-77-8 98%
    ATZ-1993 is an orally active, nonpeptide endothelin receptor subtype Aand endothelin receptor subtype B antagonist with pKi values of 8.69, 7.20, respectively. ATZ-1993 has the potential for the research of intimal hyperplasia after balloon denudation of the carotid artery.
    ATZ-1993
  • HY-122397
    Rubrolone 65445-21-8 98%
    Rubrolone is an alkaloid natural product from Streptomyces. Rubrolone has cardioprotective effects.
    Rubrolone
  • HY-12273G
    DMH-1 (GMP) 1206711-16-1 98%
    DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 (GMP) is a selective BMP inhibitor. DMH-1 (GMP) upregulates the expression of SOX1. DMH-1 (GMP) increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 (GMP) induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons.
    DMH-1 (GMP)
  • HY-122813
    Dabigatran acyl-β-D-glucuronide 1015167-40-4 98%
    Dabigatran acyl-β-D-glucuronide is an active metabolite of the thrombin inhibitor Dabigatran (HY-10163). Dabigatran acyl-β-D-glucuronide increases activated partial thromboplastin time (aPTT) in isolated human platelet-poor plasma.
    Dabigatran acyl-β-D-glucuronide
  • HY-12283R
    Rostafuroxin (Standard) 156722-18-8 98%
    Rostafuroxin (Standard) is the analytical standard of Rostafuroxin. This product is intended for research and analytical applications. Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na+,K+-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity.
    Rostafuroxin (Standard)
  • HY-12298R
    Setanaxib (Standard) 1218942-37-0 98%
    Setanaxib (Standard) is the analytical standard of Setanaxib. This product is intended for research and analytical applications. Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with Kis of 140 and 110 nM, respectively.
    Setanaxib (Standard)
  • HY-123016
    9(S)-HODE cholesteryl ester 143442-54-0 98%
    9(S)-HODE cholesteryl ester is originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid peroxidation.2 9(S)-HODE cholesteryl ester can be used as a standard for analysis of chiral HODE cholesteryl esters.
    9(S)-HODE cholesteryl ester
  • HY-123127
    CVT-2759 analog 342419-10-7 98%
    CVT-2759 analog (compound 15) is a partial agonist of A1 adenosine receptor (Ki=167 nM) and can be used for the study of cardiac arrhythmias.
    CVT-2759 analog
  • HY-123187
    AS2553627 1251906-10-1 98%
    AS2553627 is a type of JAK inhibitor, with IC50 values of 0.46, 0.30, 0.14, and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively. AS2553627 can inhibit the proliferation of human and rat T cells stimulated by IL-2, with IC50 values of 2.4 and 4.3 nM, respectively. AS2553627 can reduce cardiac allograft vasculopathy and fibrosis in a rat heart transplant model, effectively extending survival rates. AS2553627 can be used to prevent acute and chronic rejection in heart transplants.
    AS2553627
  • HY-123196
    CVT-2759 342419-09-4 98%
    CVT-2759 is a potent inhibitor of A1-ADOR, with the IC50 values of 0.18 μM and 9.5 μM to reduce the binding of [3H]CPX in the absence and presence of 1 mM GTP. CVT-2759 plays an important role in slowing AV nodal conduction and thereby ventricular rate without causing AV block, bradycardia, atrial arrhythmias, or vasodilation.
    CVT-2759
  • HY-123226
    TA-606 190602-72-3 98%
    TA-606 is a potent and orally active angiotensin II-receptor antagonist. TA-606 shows antihypertensive efficacy. TA-606 can be used for hypertension research.
    TA-606
  • HY-123227
    SQ 27786 89813-31-0 98%
    SQ 27786 is an angiotensin converting enzyme (ACE) inhibitor and a diuretic agent. SQ 27786 can be utilized in cardiovascular disease research.
    SQ 27786
  • HY-123260
    S12340 144754-35-8 98%
    S12340 is a a inhibitor of the oxidative modification of low-density lipoprotein and shows protective effect on cardiac cells exposed to oxidative stress.
    S12340
  • HY-123287
    Soquinolol 61563-18-6 98%
    Soquinolol is a β adrenergic receptor antagonist. Soquinolol plays an important role in cardiac failure research.
    Soquinolol
  • HY-123328
    AGN 191976 159359-94-1 98%
    AGN 191976 is a potent and selective thromboxane A2-sensitive (TP) receptor agonist with EC50 values ​​of 0.23 nM and 24 nM in rat aorta and human platelets, respectively. AGN 191976 has potent IOP-lowering effects in dogs and monkeys. AGN 191976 can be used to study vascular biology and the role of thromboxane A2 in vascular function.
    AGN 191976
  • HY-123356
    EMD-503982 768370-75-8 98%
    EMD-503982 is an orally available FXa inhibitor.
    EMD-503982
  • HY-123381
    Gemopatrilat 160135-92-2 98%
    Gemopatrilat (BMS-189921) is an orally active vasopeptidase inhibitor with IC50 value of 12 nM. Gemopatrilat can be used in studies of hypertension and congestive heart failure.
    Gemopatrilat
  • HY-123392
    Sch 13835 150519-34-9 98%
    Sch 13835 is a platelet-derived growth factor (PDGFR) inhibitor.
    Sch 13835
  • HY-123397
    SCH-44643 133330-43-5 98%
    SCH-44643 is an orally active platelet activating factor (PAF) and histamine antagonist.
    SCH-44643
  • HY-123428
    MSK-195 289902-82-5 98%
    MSK-195 is a potent agonist of TRPV1, with a potency of 120 nM and an efficacy of 71% in arteriolar response.
    MSK-195
Cat. No. Product Name / Synonyms Application Reactivity